Solid tumour vaccine - Northwest Biotherapeutics

Drug Profile

Solid tumour vaccine - Northwest Biotherapeutics

Alternative Names: DCVax®-Direct; DCVax®-Direct adjuvant cancer therapy; DCVax®-Head & Neck; DCVax®-Liver; DCVax®-Lung; DCVax®-Pancreas

Latest Information Update: 04 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwest Biotherapeutics
  • Developer Johannes Gutenberg-University Mainz; Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 20 Aug 2018 Northwest Biotherapeutics and Mayo Clinic plans a phase Ib trial for Brain metastases from non-small cell lung cancer or breast cancer (Inoperable/Unresectable) in USA (Intratumoural) (NCT03638765)
  • 21 Sep 2016 Efficacy data from a phase I trial in Solid tumours released by Northwest Biotherapeutics
  • 02 May 2016 Efficacy data from a phase I/II trial in Solid tumours released by Northwest Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top